Key facts
- This page summarizes Freddy A. Jimenez's Form 4 filing for Celldex Therapeutics, Inc. (CLDX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 07 Jun 2024, 16:05.
Freddy A. Jimenez - 05 Jun 2024 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)
- Reporting relationship
- SVP & GENERAL COUNSEL
- Issuer ticker
- CLDX
- Reported as of
- 05 Jun 2024
- Net transaction value
- +$99,025
- SEC form
- 4
- Accepted by SEC
- 07 Jun 2024, 16:05:16 UTC
- Prior SEC filing
- 05 Jun 2024
- Next SEC filing
- 17 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sam Martin, attorney-in-fact for Freddy A. Jimenez
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Freddy A. Jimenez filed Form 4 for Celldex Therapeutics, Inc. (CLDX) on 07 Jun 2024.
Change
- Previous filing in this sequence was filed on 05 Jun 2024.
- Current net transaction value: +$99,025.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLDX
transaction
Common Stock
Options Exercise
- Transaction value
- $99,025
- Shares
- +9,540
- Change %
- +37%
- Price
- $10.38
- Shares after
- 35,464
- Date
- 05 Jun 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLDX
transaction
Derivative
Incentive Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -9,540
- Change %
- -34%
- Price
- $0.000000
- Shares after
- 18,454
- Date
- 05 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,540
- Exercise price
- $10.38
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.